tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2020 Jul 30;8(3):E427.
doi: 10.3390/vaccines8030427.
Moderate Vaccine Effectiveness against Severe Acute Respiratory Infection Caused by A(H1N1)pdm09 Influenza Virus and No Effectiveness against A(H3N2) Influenza Virus in the 2018/2019 Season in Italy
Caterina Rizzo[SUP] 1 [/SUP], Francesco Gesualdo[SUP] 1 [/SUP], Daniela Loconsole[SUP] 2 [/SUP], Elisabetta Pandolfi[SUP] 1 [/SUP], Antonino Bella[SUP] 3 [/SUP], Andrea Orsi[SUP] 4 [/SUP], Giulia Guarona[SUP] 4 [/SUP], Donatella Panatto[SUP] 4 [/SUP], Giancarlo Icardi[SUP] 4 [/SUP], Christian Napoli[SUP] 5 [/SUP], Giovanni Battista Orsi[SUP] 6 [/SUP], Ilaria Manini[SUP] 6 7 [/SUP], Emanuele Montomoli[SUP] 7 8 [/SUP], Ilaria Campagna[SUP] 1 [/SUP], Luisa Russo[SUP] 1 [/SUP], Valeria Alfonsi[SUP] 9 [/SUP], Simona Puzelli[SUP] 3 [/SUP], Antonino Reale[SUP] 1 [/SUP], Umberto Raucci[SUP] 1 [/SUP], Livia Piccioni[SUP] 1 [/SUP], Carlo Concato[SUP] 1 [/SUP], Marta Luisa Ciofi Degli Atti[SUP] 1 [/SUP], Alberto Villani[SUP] 1 [/SUP], Maria Chironna[SUP] 2 [/SUP], Alberto Eugenio Tozzi[SUP] 1 [/SUP]
Affiliations
Abstract
Every season, circulating influenza viruses change; therefore, vaccines must be reformulated each year. We aimed to estimate vaccine effectiveness (VE) against severe influenza infection for the 2018/19 season in Italy. We conducted a test-negative design case-control study at five Italian hospitals. We estimated influenza VE against severe acute respiratory infection (SARI) requiring hospitalisation overall, and by virus subtype, vaccine brand, and age. The 2018/19 season was characterised by A(H1N1)pmd09 and A(H3N2) influenza viruses. Vaccine coverage among <18 years recruited SARI cases was very low (3.2%). Seasonal vaccines were moderately effective against type A influenza overall (adjusted VE = 40.5%; 95% confidence interval (CI) = 18.7-56.4%) and subtype A(H1N1)pmd09 viruses (adjusted VE = 55%; 95% CI = 34.5-69.1%), but ineffective against subtype A(H3N2) viruses (adjusted VE = 2.5%; 95% CI = -50.0-36.7%). Both Fluad and Fluarix Tetra vaccines were effective against type A influenza overall and subtype A(H1N1)pdm09 viruses. VE appeared to be similar across age groups (0-64 years, ≥65 years). Seasonal influenza vaccines in the 2018/19 season were moderately effective in preventing SARI caused by A(H1N1)pdm09 influenza but ineffective against A(H3N2).
Keywords: IT-BIVE-HOSP network; Italy; SARI; influenza vaccine effectiveness; test-negative case-control study.
. 2020 Jul 30;8(3):E427.
doi: 10.3390/vaccines8030427.
Moderate Vaccine Effectiveness against Severe Acute Respiratory Infection Caused by A(H1N1)pdm09 Influenza Virus and No Effectiveness against A(H3N2) Influenza Virus in the 2018/2019 Season in Italy
Caterina Rizzo[SUP] 1 [/SUP], Francesco Gesualdo[SUP] 1 [/SUP], Daniela Loconsole[SUP] 2 [/SUP], Elisabetta Pandolfi[SUP] 1 [/SUP], Antonino Bella[SUP] 3 [/SUP], Andrea Orsi[SUP] 4 [/SUP], Giulia Guarona[SUP] 4 [/SUP], Donatella Panatto[SUP] 4 [/SUP], Giancarlo Icardi[SUP] 4 [/SUP], Christian Napoli[SUP] 5 [/SUP], Giovanni Battista Orsi[SUP] 6 [/SUP], Ilaria Manini[SUP] 6 7 [/SUP], Emanuele Montomoli[SUP] 7 8 [/SUP], Ilaria Campagna[SUP] 1 [/SUP], Luisa Russo[SUP] 1 [/SUP], Valeria Alfonsi[SUP] 9 [/SUP], Simona Puzelli[SUP] 3 [/SUP], Antonino Reale[SUP] 1 [/SUP], Umberto Raucci[SUP] 1 [/SUP], Livia Piccioni[SUP] 1 [/SUP], Carlo Concato[SUP] 1 [/SUP], Marta Luisa Ciofi Degli Atti[SUP] 1 [/SUP], Alberto Villani[SUP] 1 [/SUP], Maria Chironna[SUP] 2 [/SUP], Alberto Eugenio Tozzi[SUP] 1 [/SUP]
Affiliations
- PMID: 32751584
- DOI: 10.3390/vaccines8030427
Abstract
Every season, circulating influenza viruses change; therefore, vaccines must be reformulated each year. We aimed to estimate vaccine effectiveness (VE) against severe influenza infection for the 2018/19 season in Italy. We conducted a test-negative design case-control study at five Italian hospitals. We estimated influenza VE against severe acute respiratory infection (SARI) requiring hospitalisation overall, and by virus subtype, vaccine brand, and age. The 2018/19 season was characterised by A(H1N1)pmd09 and A(H3N2) influenza viruses. Vaccine coverage among <18 years recruited SARI cases was very low (3.2%). Seasonal vaccines were moderately effective against type A influenza overall (adjusted VE = 40.5%; 95% confidence interval (CI) = 18.7-56.4%) and subtype A(H1N1)pmd09 viruses (adjusted VE = 55%; 95% CI = 34.5-69.1%), but ineffective against subtype A(H3N2) viruses (adjusted VE = 2.5%; 95% CI = -50.0-36.7%). Both Fluad and Fluarix Tetra vaccines were effective against type A influenza overall and subtype A(H1N1)pdm09 viruses. VE appeared to be similar across age groups (0-64 years, ≥65 years). Seasonal influenza vaccines in the 2018/19 season were moderately effective in preventing SARI caused by A(H1N1)pdm09 influenza but ineffective against A(H3N2).
Keywords: IT-BIVE-HOSP network; Italy; SARI; influenza vaccine effectiveness; test-negative case-control study.